Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 125

1.

Cortisol assay in dried blood spots to reduce false positive rate in congenital adrenal hyperplasia screening.

Brossaud J, Barat P, Fagour L, Corcuff JB.

Clin Chim Acta. 2012 Aug 16;413(15-16):1306-7. doi: 10.1016/j.cca.2012.04.022. Epub 2012 Apr 25. No abstract available.

PMID:
22561187
2.

Steroid profiling for congenital adrenal hyperplasia by tandem mass spectrometry as a second-tier test reduces follow-up burdens in a tertiary care hospital: a retrospective and prospective evaluation.

Seo JY, Park HD, Kim JW, Oh HJ, Yang JS, Chang YS, Park WS, Lee SY.

J Perinat Med. 2014 Jan;42(1):121-7. doi: 10.1515/jpm-2013-0154.

PMID:
23989111
3.
4.

Newborn screening for congenital adrenal hyperplasia: additional steroid profile using liquid chromatography-tandem mass spectrometry.

Janzen N, Peter M, Sander S, Steuerwald U, Terhardt M, Holtkamp U, Sander J.

J Clin Endocrinol Metab. 2007 Jul;92(7):2581-9. Epub 2007 Apr 24.

PMID:
17456574
5.

Improved precision of newborn screening for congenital adrenal hyperplasia using weight-adjusted criteria for 17-hydroxyprogesterone levels.

Allen DB, Hoffman GL, Fitzpatrick P, Laessig R, Maby S, Slyper A.

J Pediatr. 1997 Jan;130(1):128-33.

PMID:
9003862
6.

Rapid steroid hormone quantification for congenital adrenal hyperplasia (CAH) in dried blood spots using UPLC liquid chromatography-tandem mass spectrometry.

Janzen N, Sander S, Terhardt M, Steuerwald U, Peter M, Das AM, Sander J.

Steroids. 2011 Dec 11;76(13):1437-42. doi: 10.1016/j.steroids.2011.07.013. Epub 2011 Aug 2.

PMID:
21839763
7.

Comparison of newborn screening protocols for congenital adrenal hyperplasia in preterm infants.

Sarafoglou K, Gaviglio A, Hietala A, Frogner G, Banks K, McCann M, Thomas W.

J Pediatr. 2014 May;164(5):1136-40. doi: 10.1016/j.jpeds.2014.01.038. Epub 2014 Feb 28.

PMID:
24582106
8.

Concurrent Confirmation and Differential Diagnosis of Congenital Adrenal Hyperplasia from Dried Blood Spots: Application of a Second-Tier LC-MS/MS Assay in a Cross-Border Cooperation for Newborn Screening.

Monostori P, Szabó P, Marginean O, Bereczki C, Karg E.

Horm Res Paediatr. 2015;84(5):311-8. doi: 10.1159/000439380. Epub 2015 Sep 24.

PMID:
26397944
9.

Newborn screening for congenital adrenal hyperplasia in Cuba: six years of experience.

González EC, Carvajal F, Frómeta A, Arteaga AL, Castells EM, Espinosa T, Coto R, Pérez PL, Tejeda Y, Del Río L, Segura MT, Almenares P, Robaina R, Fernández JL.

Clin Chim Acta. 2013 Jun 5;421:73-8. doi: 10.1016/j.cca.2013.02.020. Epub 2013 Feb 26.

PMID:
23481450
10.

Weight-adjusted neonatal 17OH-progesterone cutoff levels improve the efficiency of newborn screening for congenital adrenal hyperplasia.

Hayashi G, Faure C, Brondi MF, Vallejos C, Soares D, Oliveira E, Brito VN, Mendonca BB, Bachega TA.

Arq Bras Endocrinol Metabol. 2011 Nov;55(8):632-7.

11.

Improved specificity of newborn screening for congenital adrenal hyperplasia by second-tier steroid profiling using tandem mass spectrometry.

Lacey JM, Minutti CZ, Magera MJ, Tauscher AL, Casetta B, McCann M, Lymp J, Hahn SH, Rinaldo P, Matern D.

Clin Chem. 2004 Mar;50(3):621-5. Epub 2003 Dec 4.

12.

Corrected 17-alpha-hydroxyprogesterone values adjusted by a scoring system for screening congenital adrenal hyperplasia in premature infants.

Lee JE, Moon Y, Lee MH, Jun YH, Oh KI, Choi JW.

Ann Clin Lab Sci. 2008 Summer;38(3):235-40.

PMID:
18715851
13.

Steroid profiling by tandem mass spectrometry improves the positive predictive value of newborn screening for congenital adrenal hyperplasia.

Minutti CZ, Lacey JM, Magera MJ, Hahn SH, McCann M, Schulze A, Cheillan D, Dorche C, Chace DH, Lymp JF, Zimmerman D, Rinaldo P, Matern D.

J Clin Endocrinol Metab. 2004 Aug;89(8):3687-93.

PMID:
15292289
14.

A three-year follow-up of congenital adrenal hyperplasia newborn screening.

Pezzuti IL, Barra CB, Mantovani RM, Januário JN, Silva IN.

J Pediatr (Rio J). 2014 May-Jun;90(3):300-7. doi: 10.1016/j.jped.2013.09.007. Epub 2014 Feb 18.

15.

Antenatal corticosteroids and newborn screening for congenital adrenal hyperplasia.

King JL, Naber JM, Hopkin RJ, Repaske DR, Bailey L, Leslie ND.

Arch Pediatr Adolesc Med. 2001 Sep;155(9):1038-42.

PMID:
11529806
16.
17.

Use of steroid profiling by UPLC-MS/MS as a second tier test in newborn screening for congenital adrenal hyperplasia: the Utah experience.

Schwarz E, Liu A, Randall H, Haslip C, Keune F, Murray M, Longo N, Pasquali M.

Pediatr Res. 2009 Aug;66(2):230-5. doi: 10.1203/PDR.0b013e3181aa3777.

PMID:
19390483
18.

Hormonal disturbances due to severe and mild forms of congenital adrenal hyperplasia are already detectable in neonatal life.

Faurschou S, Mouritsen A, Johannsen TH, Hougaard DM, Cohen A, Duno M, Juul A, Main KM.

Acta Paediatr. 2015 Feb;104(2):e57-62. doi: 10.1111/apa.12835. Epub 2014 Nov 17.

PMID:
25346389
19.

Transient hyper-17-hydroxyprogesteronemia: a clinical subgroup of patients diagnosed at neonatal screening for congenital adrenal hyperplasia.

Cavarzere P, Samara-Boustani D, Flechtner I, Dechaux M, Elie C, Tardy V, Morel Y, Polak M.

Eur J Endocrinol. 2009 Aug;161(2):285-92. doi: 10.1530/EJE-09-0145. Epub 2009 May 18.

20.

Effect of single and multiple courses of prenatal corticosteroids on 17-hydroxyprogesterone levels: implication for neonatal screening of congenital adrenal hyperplasia.

Gatelais F, Berthelot J, Beringue F, Descamps P, Bonneau D, Limal JM, Coutant R.

Pediatr Res. 2004 Nov;56(5):701-5. Epub 2004 Sep 15.

PMID:
15371568

Supplemental Content

Support Center